BackAvineuro advances second drug candidate to clinical development for treatment of Alzheimer’s disease.
San Diego, CA – November 3rd, 2008 – Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Alzheimer’s disease. These studies demonstrate that AVN-211 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-211 into clinical trials in Q1 2009. Results of the studies will be presented at the 9th International Conference – AD/PD 2009 – Prague, Czech Republic, March 11-15, 2009.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email:YLavrovsky@avineuro.com